Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1063-1070.doi: 10.35541/cjd.20210324
• Original Articles • Previous Articles Next Articles
Song Xiaoting1, Liu Bo1, Chen Yudi2, Yu Miao1,3, Liao Shuanglu1, Luan Tingting1,3, Zhao Zuotao1
Received:
2021-04-21
Revised:
2021-09-21
Online:
2021-12-15
Published:
2021-12-01
Contact:
Zhao Zuotao
E-mail:zhaozuotaotao@163.com
Supported by:
Song Xiaoting, Liu Bo, Chen Yudi, Yu Miao, Liao Shuanglu, Luan Tingting, Zhao Zuotao. Efficacy and safety of omalizumab for treatment of chronic spontaneous urticaria[J]. Chinese Journal of Dermatology, 2021, 54(12): 1063-1070.doi:10.35541/cjd.20210324
[1] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[2] | 张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021,54(7):582⁃585. doi: 10.35541/cjd.20201261. |
[3] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1):1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
[4] | Konstantinou GN, Asero R, Maurer M, et al. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria[J]. Allergy, 2009,64(9):1256⁃1268. doi: 10.1111/j. 1398⁃9995.2009.02132.x. |
[5] | Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient⁃reported outcome instrument for assessing urticaria control[J]. J Allergy Clin Immunol, 2014,133(5):1365⁃1372,1372.e1⁃e6. doi: 10.1016/ j.jaci.2013.12.1076. |
[6] | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190. |
[7] | Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal important difference of the urticaria control test[J]. J Allergy Clin Immunol, 2017,140(6):1710⁃1713.e11. doi: 10. 1016/j.jaci.2017.04.050. |
[8] | Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)⁃⁃a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994,19(3):210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x. |
[9] | Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ′real⁃world′ evidence[J]. Expert Opin Biol Ther, 2018,18(4):425⁃448. doi: 10.1080/14712598.2018.1438406. |
[10] | Apalla Z, Sidiropoulos T, Kampouropoulou E, et al. Real⁃life, long⁃term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria[J]. Eur J Dermatol, 2020,30(6):716⁃722. doi: 10.1684/ejd.2020.3919. |
[11] | Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta⁃analysis of "real⁃world" evidence[J]. JAMA Dermatol, 2019,155(1):29⁃38. doi: 10.1001/jamadermatol.2018.3447. |
[12] | Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306. |
[13] | Curto⁃Barredo L, Spertino J, Figueras⁃Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria[J]. Br J Dermatol, 2018,179(1):210⁃212. doi: 10.1111/bjd.16379. |
[14] | Asero R, Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications[J]. Expert Rev Clin Immunol, 2021,17(3):247⁃254. doi: 10.1080/1744666X.2021.1882304. |
[15] | Fok JS, Kolkhir P, Church MK, et al. Predictors of treatment response in chronic spontaneous urticaria[J]. Allergy, 2021,76(10):2965⁃2981. doi: 10.1111/all.14757. |
[16] | Choi JH, Lee DH, Song WJ, et al. The KAAACI/KDA evidence⁃based practice guidelines for chronic spontaneous urticaria in Korean adults and children: part 2. Management of H1⁃antihistamine⁃refractory chronic urticaria[J]. Allergy Asthma Immunol Res, 2020,12(5):750⁃770. doi: 10.4168/aair.2020.12. 5.750. |
[17] | Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria[J]. Ann Allergy Asthma Immunol, 2015,115(2):126⁃129. doi: 10.1016/j.anai. 2015.05.010. |
[18] | Labrador⁃Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real⁃life practice[J]. Expert Opin Biol Ther, 2013,13(9):1225⁃1228. doi: 10.1517/14712598.2013.822484. |
[19] | Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab[J]. J Allergy Clin Immunol, 2008,122(3):569⁃573. doi: 10.1016/j.jaci.2008.07.006. |
[20] | Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab[J]. Acta Derm Venereol, 2010,90(4):443⁃444. doi: 10.2340/00015555⁃0884. |
[21] | Lefévre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria[J]. Ann Dermatol, 2013,25(2):242⁃245. doi: 10.5021/ad.2013.25.2.242. |
[22] | Kai AC, Flohr C, Grattan CE. Improvement in quality of life impairment followed by relapse with 6⁃monthly periodic administration of omalizumab for severe treatment⁃refractory chronic urticaria and urticarial vasculitis[J]. Clin Exp Dermatol, 2014,39(5):651⁃652. doi: 10.1111/ced.12320. |
[23] | Subramaniyan R, Chopra A. Treatment of chronic spontaneous urticaria with a single dose of omalizumab: a study of four cases[J]. Indian J Dermatol, 2016,61(4):467. doi: 10.4103/0019⁃5154.185745. |
[24] | Mandel VD, Guanti MB, Liberati S, et al. Omalizumab in chronic spontaneous urticaria refractory to conventional therapy: an italian retrospective clinical analysis with suggestions for long⁃term maintenance strategies[J]. Dermatol Ther (Heidelb), 2018,8(2):291⁃301. doi: 10.1007/s13555⁃018⁃0240⁃7. |
[25] | Maurer M, Kaplan A, Rosén K, et al. The XTEND⁃CIU study: long⁃term use of omalizumab in chronic idiopathic urticaria[J]. J Allergy Clin Immunol, 2018,141(3):1138⁃1139.e7. doi: 10. 1016/j.jaci.2017.10.018. |
[26] | Su O, Bahali AG, Onsun N. The effect of at least 1⁃year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria[J]. Dermatol Ther, 2020,33(6):e14192. doi: 10.1111/dth.14192. |
[27] | Acar A, Gerceker Turk B, Ertam Sagduyu I, et al. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience[J]. Cutan Ocul Toxicol, 2020,39(3):249⁃253. doi: 10.1080/15569527.2020.178 7432. |
[28] | Ocak M, Soyer O, Buyuktiryaki B, et al. Omalizumab treatment in adolescents with chronic spontaneous urticaria: efficacy and safety[J]. Allergol Immunopathol (Madr), 2020,48(4):368⁃373. doi: 10.1016/j.aller.2020.03.011. |
[29] | Papaianni V, Guarneri F, Vaccaro M, et al. From regulatory limitations to new opportunities: real⁃life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria[J]. Dermatol Ther, 2020,33(1):e13188. doi: 10.1111/dth.13188. |
[30] | Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty⁃five patients[J]. Allergol Int, 2018,67(1):85⁃89. doi: 10.1016/j.alit.2017.05.003. |
[31] | Sardana K, Dixit N, Arora P. A real⁃world analysis of relapse rate and efficacy of a restricted monthly dose of omalizumab in recalcitrant chronic spontaneous urticaria in India[J]. Indian Dermatol Online J, 2020,11(5):835⁃837. doi: 10.4103/idoj.IDOJ_499_19. |
[32] | Vadasz Z, Tal Y, Rotem M, et al. Omalizumab for severe chronic spontaneous urticaria: real⁃life experiences of 280 patients[J]. J Allergy Clin Immunol Pract, 2017,5(6):1743⁃1745. doi: 10. 1016/j.jaip.2017.08.035. |
[33] | Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(5):918⁃924. doi: 10.1111/jdv.15350. |
[34] | Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2017,140(6):1749⁃1751. doi: 10.1016/j.jaci.2017.08.007. |
[35] | Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022. |
[36] | Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria[J]. JAMA Dermatol, 2014,150(3):288⁃290. doi: 10.1001/jamadermatol.2013.8705. |
[37] | Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria[J]. J Allergy Clin Immunol Pract, 2019,7(5):1659⁃1661.e1. doi: 10.1016/j.jaip.2018.11.018. |
[38] | Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria[J]. Clin Exp Allergy, 2020,50(7):799⁃804. doi: 10. 1111/cea.13616. |
[39] | Sand FL, Thomsen SF. Off⁃label use of TNF⁃alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients[J]. Dermatol Ther, 2015,28(3):158⁃165. doi: 10.1111/dth.12222. |
[40] | Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa12 15372. |
[1] | Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 0(4): 20220278-e20220278. |
[2] | Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362. |
[3] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[4] | Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553. |
[5] | Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354. |
[6] | Zhou Tiantian, Wu Xuege, Yang Huan, Fang Xiao, Jiang Jinqiu, Chen Jingsi, Luo Xiaoyan, Wang Hua. Analysis of the etiology and factors associated with the severity of chronic spontaneous urticaria in children [J]. Chinese Journal of Dermatology, 2024, 57(4): 324-330. |
[7] | Tian Jing, Deng Sisi, Song Zhiqiang . A comparison of clinical characteristics between atopic and non-atopic prurigo nodularis [J]. Chinese Journal of Dermatology, 2024, 57(4): 331-337. |
[8] | Li Yuanjun, Han Yuyang, Zhang Huanzhen, Wang Hui, Shen Nan, Zhang Xinglian. Dupilumab in the treatment of 12 children with chronic spontaneous urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(3): 254-257. |
[9] | Enze LI Lu CHEN Chu-Qiao ZHANG Jiao qingqing JI Jiang. Correlations of gut microbiota and short-chain fatty acids with chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230310-e20230310. |
[10] | Zhang Qian, Zhang Jin′e, Guo Sen, Song Pu, Gao Lin, Li Chunying. Comparison of the efficacy of fractional CO2 laser combined with topical delivery of fluorouracil versus compound betamethasone injections in the treatment of vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2024, 57(1): 34-38. |
[11] | Liu Yuanxiang, Liang Yuan, Zhao Xinrong, Sun Yujuan, Ma Lin, Xu Zigang. Janus kinase inhibitors for the treatment of five children with severe alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 849-852. |
[12] | Wang Junxia, Guo Weinan, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Efficacy of autologous fat grafting in the treatment of 40 cases of stable linear scleroderma: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(8): 762-765. |
[13] | Zhou Tong, Geng Songmei. Application of biologic agents in the treatment of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2023, 56(8): 789-793. |
[14] | Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566. |
[15] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023)” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |